Introduction：Basic information about CAS 637334-45-3|Ocrelizumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Ocrelizumab |
|---|
| CAS Number | 637334-45-3 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Ocrelizumab |
|---|
| Synonym | More Synonyms |
|---|
Ocrelizumab BiologicalActivity
| Description | Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)[1]. |
|---|
| Related Catalog | Research Areas >>Inflammation/Immunology |
|---|
| References | [1]. Mulero P, et al. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018 May 10;11:1756286418773025. |
|---|
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
Synonyms
| Monoclonal antibody Pro70769 |
| Pro-70769 |
| Pro70769 |
| Rhumab 2H7 |
